The 2018 cohort of teams are developing new technologies addressing a range of unmet medical needs, including veterans’ hearing loss, cancer screening, and obesity. Read the news announcement introducing the teams.
Proposals to IDEA² Global were invited from anywhere in the world and are sponsored by several organizations dedicated to biomedical technology innovation. Project sponsors include Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE, a Spain-based nonprofit dedicated to advancing new healthcare technologies), the MIT Institute for Medical Engineering and Science (IMES), MassBIO, Cantabria Labs (a Spain-based pharmaceutical R&D company), the Medicine Innovation Program at Massachusetts General Hospital, the US Department of Veterans Affairs, and MIT Hacking Medicine.
A new strategy to fight against viral retrotranscription
Chronic treatment of HIV is hampered by severe adverse effects of treatments and virus ability to evade new drugs by continuous evolution and mutation. Our strategy targets a surface protein on the host cell named CD81, not encoded in the virus genome and therefore not affected by viral mutations. We have designed CD81blocking peptides that have proven to reduce HIV infection of healthy human T-lymphocytes. This strategy would benefit patients with resistant forms of the HIV virus, and can be also useful for other viral infections such as Herpes
Team: Henar Suarez Montero, Ester García, María Yáñez-Mó, Vera Rocha-Perugini, Francisco Sánchez-Madrid, Antonio Rodríguez Hita, Victor Toribio
Ear Level Activity Tracking/Falls Detection and Prevention
A project to identify and test a minimal viable product that integrates sensor technology for activity tracking and falls detection/prevention with a hearing aid
Team: Crystal Mata, Deep Garg, Michael Lindeman, Denice McGilvery
A number of retinal diseases such as diabetic retinopathy can cause blindness if not detected early. We have developed a Retinoscope witch takes images of the eye funds with independent light source and optics and that can be used without expertise, so this will allow saving the vision of the patients that are being misdiagnosed nowadays. The open retinoscope is a new device that allows the visualization of the retina of a patient, and has proved, a bigger field of vision than any direct ophthalmoscope, and allows the coupling of any smartphone of the market, to obtain images and videos of the eye fundus. With the intention of improving the medical care provided to ophthalmologic patients, bringing our device to the market and making it available to health professionals who need it, we are trying to identify and develop a list of stakeholders that allows us to reach our objective.
Team: Florencio González Márquez, Luis Castillón Torres, Pablo Hervás Ballesteros, Francisco Javier Hernández Martínez, Luis Luque Romero, José Luis García Garmendia, Gorka Gómez Ciriza, Cristina Suarez Mejías, Tomas Gómez CIA
Circulating tumor cells nanoplasmonic biosensor (CTCnanoSen)
Currently only about 10% of cancer patients have their circulating tumor cells detected. The existing technologies to detect them are expensive, need expert operators and most of them do not preserve the tumor cells. We propose a new generation of optical based devices able to detect, count and analyze circulating tumor cells, overcoming the disadvantages of current technologies.
Team: Alfredo Franco, Jose Luis Fdez. Luna, Fernando Moreno, Francisco Gonzalez, Santos Merino
10M of endoscopic resections are performed every year in US and EU. This induces a growing number of complications, including perforation, because our current closure system with clips is inefficient in the 5% of the cases. We develop a new approach based on the endoscopic administration of a novel and patented hydrogel (CoverGel), first in class, specifically designed to induce mucosal restoration and protect the eschars as a shield to solve this situation.
Team: Vicente Lorenzo-Zúñiga García, Ramon Bartoli Solé
“PEPSTOB” (Peptide to stop obesity)
It is known that a protein called sex hormone-binding globulin (SHBG) is reduced in obese subjects. We have shown that artificially increasing this protein in mouse models reduces obesity, and further, we identified which peptides within the protein are responsible for the protective effects. This may provide a novel and safe therapeutic pathway to treat obesity.
Team: David Martinez Selva, Antonio Herce Sesa, Rafael Simo Canonge, Laura Brianso Llort,Lorena Ramos Perez, Lidia Fuertes Rioja
Did you know that there are 500 girls born without a vagina in the U.S. every year? There are surgical solutions to reconstruct a vagina when they become teens. However, the surgery is complicated and requires a large skin graft that often fails. Our product overcomes the need for a skin graft, by allowing natural skin to grow just like it happens when we make a piercing, shortening surgical time, giving comfort to the patients, and improving results.
Team: Maribel Acien, Pedro Acién, Miguel Sánchez-Lozano, Miguel Ángel Oliva-Meyer, Javier Martínez García, María Prada, Begoña García-Jaén
Creating a Patient-Centered Smartphone or Computer Application for Cirrhosis Management
Patients with cirrhosis can self-manage their disease according to expert guidelines with a Smartphone application that uses tracking tools, notifications, and other cirrhosis-specific assessments, in order to reduce hospital readmissions and save hospitals and insurance companies up to $2000 per patient per year.
Team: Patricia Pringle, James Richter, Raymond Chung, Madeleine Marx, Sarah Argyropoulos, Stephanie Rutledge
Translational Neuroscience Center
As part of the Boston Chidren’s Hospital, we leverage our unique access to patients with neurodvelopmental disorders, such as epilepsy, and developed a patient-driven platform to derisk clinical trial in neuroscience, using our demonstrated highly translatable preclinical assays to identify and validate druggable targets.
Team: Ivy Cheng, Elizabeth Buttermore, Sameer Dhamne, Sean Dwyer, Denise McGinnins, Meera Modi
Therapeutics by Ellie
Patient neuroimaging has shown neurocircuit activity to be a robust biomarker of mental health conditions. However, establishing a neural circuit approach for treating mental illnesses has been impeded by an inability to link behavior to neurocircuitry in model systems. At Therapeutics by Ellie, we leverage a proprietary discovery platform to identify novel circuit pathways for therapeutic intervention and assess circuit-specific drug activity in translational model systems. For individuals suffering from a mental illness, Therapeutics by Ellie focuses on development of transformative medicines that not only engage a target in the traditional sense but also affects the neurocircuitry relevant to the behavioral/cognitive phenotype of the disorder.
Project lead: Adam Vogel
We have developed a heart rhythm monitor capable of reliably detecting infrequently occurring atrial fibrillation symptoms by using our advanced analysis algorithm to generate high quality heart rhythm waveforms from a new sensing method so that patient diagnosis times can be cut from an average of five years, to just six weeks, saving the healthcare system $8,700 dollars per patient, per year.
Team: Oisin Mc Grath, Jaffry Syed Kumail, Belén Enguix
Bloomer Health Tech
Physicians and women diagnosed with heart disease can effortlessly and continuously monitor heart disease using our medical-grade bra which is powered by analytics that build personalized health reports and insights for targeted disease treatment, management.
Team: Mónica Abarca, Alicia Chong, Aceil Halaby, Ben Linville-Engler
augGI helps pharma research organizations conducting clinical trials related to digestive disorders reduce the time required to complete these trials by X% by increasing the % of patients that report objective longitudinal data. augGI leverages smartphones and computer vision algorithms to allow patients to seamlessly capture consistent and objective measurements of their stool outputs.
Team: David Hachuel, Akshay Jha, Lea Fayad, Shawn Dimantha, Alfonso Martinez